Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-06380101 is an auristatin microtubule inhibitor and is a cytotoxic Dolastatin 10 analogue. When compared to other synthetic auristatin analogues that are used in the preparation of ADCs, PF-06380101 displays excellent potencies in tumor cell proliferation assays and differential ADME properties.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,500 | 10-14周 | ||
50 mg | ¥ 13,700 | 10-14周 | ||
100 mg | ¥ 18,700 | 10-14周 |
产品描述 | PF-06380101 is an auristatin microtubule inhibitor and is a cytotoxic Dolastatin 10 analogue. When compared to other synthetic auristatin analogues that are used in the preparation of ADCs, PF-06380101 displays excellent potencies in tumor cell proliferation assays and differential ADME properties. |
体内活性 | PF-06380101 is anticipated to be of low risk to perpetrate pharmacokinetic drug interactions with compounds for which CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and/or CYP3A4/5-mediated metabolism constitutes the primary mechanism of clearance. PF-06380101 preferentially distributes into human plasma relative to whole blood and that PF-06380101 is a P-glycoprotein (P-gp) substrate. PF-06380101 exhibited a mean systemic clearance (Cl) of 70 mL/min/kg and a volume of distribution (Vss) of 14.70 L/kg after an IV dose of 20a at 20 μg/kg to Wistar Han rats, resulting in a terminal elimination half-life (t1/2) of approximately 6 h. The utility of the new auristatin analogues as ADC payloads including the development of the lead analogue 20a (PF-06380101) will be reported in due course. |
别名 | Auristatin-0101, Aur0101 |
分子量 | 743.01 |
分子式 | C39H62N6O6S |
CAS No. | 1436391-86-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 65 mg/mL (87.48 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.3459 mL | 6.7294 mL | 13.4588 mL | 33.6469 mL |
5 mM | 0.2692 mL | 1.3459 mL | 2.6918 mL | 6.7294 mL | |
10 mM | 0.1346 mL | 0.6729 mL | 1.3459 mL | 3.3647 mL | |
20 mM | 0.0673 mL | 0.3365 mL | 0.6729 mL | 1.6823 mL | |
50 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.6729 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PF-06380101 1436391-86-4 Others PF 06380101 Auristatin-0101 PF06380101 Aur0101 Inhibitor inhibitor inhibit